Clinical use of CSF biomarkers in a changing Alzheimer’s landscape

Introduction

Take This Event

A medical webinar to address that patients do not receive accurate and/or timely clinical and biomarker diagnoses in the early
symptomatic stages of the AD continuum due to HCP’s limited understanding of the benefits
and limited access to relevant Dx tools.

Objectives

Understanding the value of fluid biomarkers and how to implement them in clinical
routine for AD diagnosis pose barriers to the adoption of routine biomarker testing -
• What is the anticipated evolution of the patient journey?
• What are the hurdles and the potential solutions for Alzheimer's disease diagnosis?
• Considerations for Tau and amyloid CSF biomarker ratios: performance and interpretation

Speaker

Prof. Charlotte Teunissen

Professor in Neurochemistry, Chair ofthe Neurochemistry lab, AmsterdamUMC

Prof. Kaj Blennow

Professor and Academic Chair in Neurochemistry, University of Gothenburg and Sahlgrenska University Hospital.

Dr. Marc Suárez-Calvet

Barcelonaβeta Brain Research Center (BBRC), Neurology Department, Hospital del Mar, Barcelona ,Spain.